Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers

ISSN: 1875-6301 (Online)
ISSN: 1573-3947 (Print)

Volume 13, 2 Issues, 2017

Download PDF Flyer

Current Cancer Therapy Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Kurt S. Zaenker
Institute of Immunology and Experimental Oncology University Witten/Herdecke
Stockumerstraße 10, 58448 Witten

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers

Current Cancer Therapy Reviews, 9(4): 265-277.

Author(s): Ana Paula Delgado, Pamela Brandao, Sheilin Hamid and Ramaswamy Narayanan.

Affiliation: Department of Biological Sciences, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, FL 33431.


The post genome era has ushered us into therapeutic target discovery empowering us to mine the genome using rational approaches. Numerous cancer targets have emerged from the genome project for diagnostics, therapeutics and response to therapy prediction. Among thousands of genes predicted in the human genome, nearly half of them remain uncharacterized. Considerable attention in the last decade has focused on the well-characterized known genes. However, the future of cancer target discovery resides in the uncharacterized or novel genes called the dark matter of the human genome. Realizing the importance of this vast untapped potential, recently the US National Cancer Institute announced a new initiative called "Illuminating the Dark Matter of the Genome for Druggability". This area of cancer research albeit exciting, remains a challenge due to the lack of adequate information about the uncharacterized genes. Amongst the plethora of bioinformatics tools and databases, a streamlined approach remains elusive. In this review, we present a simplified approach to mine directly the cancer proteome for rapid target discovery. Using such an approach, we have created a database of uncharacterized cancer genes and have shown the biomarker and drug target potential for an uncharacterized protein, C1ORF87, as a putative solid tumor target. In view of this protein's association with carcinomas, the C1ORF87 is termed as Carcinoma-Related EF-Hand (CREF) gene. The approaches discussed in this review should aid in lighting the dark matter of the human cancer proteome.


Post genome, druggable genes, uncharacterized genes, C1ORF87, CREF gene.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 4
First Page: 265
Last Page: 277
Page Count: 13
DOI: 10.2174/1573394710666140313003905

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science